Performance of the OncoMate® MSI Dx Analysis System
In this webinar, you will learn:
- The use of MSI status for Lynch Syndrome screening in colorectal cancer (CRC)
- MSI detection using PCR followed by capillary electrophoresis (CE) analysis
- The performance characteristics of the OncoMate® MSI Dx Analysis System as an aid to identify colorectal cancer (CRC) patients who may benefit from further testing to diagnose Lynch syndrome, the most common form of hereditary CRC
Summary
Screening cancer patients for microsatellite instability (MSI) can provide pathologists, oncologists, and patients with information that characterizes tumors to help guide care and make more informed decisions. With the growing demand for MSI testing and recognition of its value as a biomarker, the need for a reliable and cost-effective MSI test has increased in recent years. In this presentation, Ms. Oostdik will discuss the new OncoMate® MSI Dx Analysis System, a FDA-cleared PCR-based MSI kit. The system uses the most sensitive panel of markers for MSI status detection, as included in multiple clinical guidelines. Topics in this presentation will include assay design, intended use, and clinical performance of OncoMate® MSI. The automated analysis software included in the system will also be discussed.
Speaker
Kathryn Oostdik
Senior Global Product Manager, Clinical Diagnostics
Promega Corporation
Kathryn Oostdik is a Sr. Global Product Manager, Clinical Diagnostics, at Promega Corporation. In her role, she provides product support to clinical markets and initiates new product development, most notably the FDA-cleared and CE-IVD marked OncoMate® MSI Dx Analysis Systems. Prior to her current position, Kathryn gained 15 years of experience developing fluorescent multiplex PCR systems for forensic applications at Promega. Kathryn received her Bachelor of Science in Medical Microbiology and Immunology, and her Masters of Biotechnology from the University of Wisconsin.